tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Cytokinetics price target raised to $56 from $52 at BofA

BofA raised the firm’s price target on Cytokinetics (CYTK) to $56 from $52 and keeps a Neutral rating on the shares. The firm, which tells investors that the company “laid out a strong case” for aficamten over an in-depth discussion during the firm’s SF Bus Tour, doesn’t disagree that “the data for the next-gen CMI look very competitive,” but it would argue debate remains on execution.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1